Hospira HSP

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Not so fast, Mylan

      Headlines

      Wed, 20 Aug 2014

      allow the sale of generic versions of Hospira 's ( HSP +1.4% ) sedative Precedex ..... injection) In its lawsuit filed yesterday, Hospira claims that the agency violated its own ..... intensive care unit sedation) covered by Hospira 's patent. In his order, Judge Jarrod

    2. U.S. judge blocks FDA rule allowing generic versions of Hospira drug

      Headlines

      Wed, 20 Aug 2014

      Aug 20 (Reuters) - A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

    3. Mylan launches generic version of Precedex

      Headlines

      Tue, 19 Aug 2014

      Mylan ( MYL +1.3% ) launches dexmedetomidine hydrochoride injection, 100 mcg (base)/mL, the therapeutic equivalent of Hospira 's ( HSP -2.8% ) Precedex . The U.S. market is ~$156M. Mylan has 295 ANDAs pending FDA approval representing

    4. UPDATE 1-Top U.S. lawmaker urges Hospira not to flee tax system

      Headlines

      Thu, 14 Aug 2014

      (Adds details of Durbin letter, Wyden comment, background, byline)

    5. Senior U.S. lawmaker urges Hospira not to flee U.S. tax system

      Headlines

      Thu, 14 Aug 2014

      WASHINGTON, Aug 14 (Reuters) - A senior U.S. senator said on Thursday he has written to the chief executive of Hospira Inc and urged the drug and medical device maker not to move its tax domicile...

    6. New Morningstar Analyst Report for Cubist Pharmaceuticals Inc

      Stock Reports

      Wed, 13 Aug 2014

      Cubicin is facing a patent challenge from Hospira .If Cubist's CB-315/Surotomycin ..... news was a big win for Cubist, but Hospira has now also challenged the drug's patent. There is a risk that Hospira could prevail in litigation, and Cubicin

    7. CareFusion Ends Fiscal Year on Strong Note as Outlook Matches Our Expectations

      Commentary

      Fri, 8 Aug 2014

      infusion pump sales surging 40%; the company should continue to benefit from ongoing market share gains as competitors like Hospira struggle with regulatory issues. The company has also made progress in the installation of its Pyxis ES system, which led

    8. New Morningstar Analyst Report for Hospira Inc

      Stock Reports

      Tue, 5 Aug 2014

      consent decree. A 2014 patent expiration on Hospira 's branded anesthetic Precedex and commencement ..... the company's profitability.Sales of Hospira 's medical devices should remain depressed ..... removed and hospital spending improves. Hospira is one of the first companies to successfully

    9. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Mon, 4 Aug 2014

      dialysis drug payments), potential branded competition (Mircera as early as 2014), and biosimilar launches (including Hospira in 2016). For neutropenia drugs Neupogen and Neulasta, we see sales declining from $5.8 billion in 2013 to $4.3 billion

    10. Hospira's (HSP) CEO Michael Ball on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Wed, 30 Jul 2014

      Hospira (NYSE: HSP ) Q2 2014 Earnings Call July 30, 2014 9:00 am ET Executives Karen King - F. Michael Ball - Chief Executive Officer

    « Prev12345Next »
    Content Partners